Endotel function and thrombotic system evaluation of children whose parents had early onset coronary heart disease

Yıl 2011, Cilt: 46 Sayı: 1, 20 - 25, 01.03.2011

Naci Öner Rukiye Eker Eker Ömeroğlu Taner Yavuz Helen Bornaun Ümrah Aydoğan Aygün Dindar Türkan Ertuğrul Ümit Türkoğlu

https://doi.org/10.4274/tpa.46.04

Öz

Aim: First degree relatives of patients who have had an acute myocardial infarction prior to age of 55 years have 2 7 times the risk that their peers have The aim of this study was to investigate some haemostatic and inflammatory markers in children whose parents had early onset lt;55 years coronary artery disease CAD and whether those markers were effective to show CAD risk

Anahtar Kelimeler

-

Ebeveynleri erken koroner kalp hastalığı geçirmiş çocuklarda endotel işlevi ve trombotik sistem değerlendirmesi

Öz

Amaç: Bu çal›flman›n amac›; anne ve/veya babas› 55 yafl›n alt›nda koroner arter hastal›¤› (KAH) geçirmifl olan çocuklarda baz› hemostatik ve enflamatuar belirteçlerin düzeylerini araflt›rmak ve bu belirteçlerin KAH’›n geliflme riskini göstermede etkili olup olmad›¤›n› belirlemektir.

Gereç ve Yöntem: Bu ileriye dönük çal›flma Fakülte Yerel Etik Kurul izniyle ‹stanbul T›p Fakültesi, Çocuk Kardiyolojisi Bilim Dal›’nda yap›lm›flt›r. Ailesinde 55 yafl alt›nda KAH olan 43 sa¤l›kl› çocuk ayn› yafl ve cinsiyetteki sa¤l›kl› kontrollerle efllefltirilerek doku faktörü (DF), serbest ve toplam doku faktörü yolu inhibitörü (DFY‹), fibrinojen, von Willebrand faktör (vWF) ve yüksek duyarl›kl› CRP (hsCRP) düzeyi belirlendi. Verilerin analizi SPSS 10 program› ile student-t ve Mann-Whitney U testleri kullan›larak yap›ld›.

Bulgular: Çal›flma grubunda vWF düzeyleri kontrol grubuna göre daha yüksek bulundu [116,3±52,2 ve 86,8±41,4 ng/mL, (p<0,05)]. ‹ki grup aras›nda DF, toplam ve serbest DFY‹, fibrinojen ve hsCRP yönünden istatistiksel olarak anlaml› farkl›l›k saptanmad›.

Çıkarımlar: Özellikle erken yaflta KAH geçirmenin temelinde genetik etmenlerin oldu¤unun bilinmesine karfl›n, bizim çal›flmam›zda ebeveynlerinde erken yaflta KAH öyküsü olan çocuklarda vWF d›fl›ndaki hemostatik ve enflamatuar belirteçler ba¤›ms›z bir risk etmeni olarak gösterilememifltir.

Anahtar Kelimeler

Doku faktörü, doku faktörü yolu inhibitörü, erken yaflta ortaya ç›kan koroner arter hastal›¤›, fibrinojen, von Willebrand faktör, yüksek duyarl›l›kl› C-reaktif protein

Kaynakça

• Onat A, Hergenç G, Yıldırım B, ve ark. Türk erişkinlerde kanda fibrinojen düzeyleri ve bazı risk parametreleri ile ilişkileri. TKD 2000; 28: 115-20. (Abstract)
• Al-Nozha MM, Abdel-Gader AM, Arafah MR, Al-Maatouq MA, Al-Shahid MS, Al-Harthi SS. Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes. Saudi Med J 2005; 26: 937-42. (Abstract)
• Gürsel T. Von willebrand hastalığı Türk toplumundaki prevalansı, kliniği ve genetik özellikleri. II. Ulusal Tromboz, Hemostaz ve Anjioloji Kongresi. Kasım, Türkiye, İstanbul; özet kitabı: 2001:29-32.
• Napoli C, Glass CK, Witztum JL, et al. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: fate of early lesions in children (FELIC) study. Lancet 1999; 354: 1234-41. (Abstract) / (Full Text) / (PDF)
• Makris TK, Hatzizacharias AN, Krespi PG, et al. Markers of risk in young offspring with paternal history of myocardial infarction. Intern J Cardiol 2003; 89: 287-93. (Abstract) / (Full Text) / (PDF)
• Pankow JS, Folsom AR, Province MA, et al. Family history of ischemic heart disease and hemostatic variables in middle aged adults. Thromb Haemost 1997; 77: 87-93.(Abstract)
• Nathan DG, Orkin SH. Nathan and Oski’s Hemotology of Infancy and Childhood. 5thedition, volume 2. Philedelphia: WB Saunders Company, 2002; 1631-59.
• Robinson DM, Schwahn C, Alte D, John U, Felix SB, Völzke H. Plasma fibrinogen levels are associated with a strong family history of myocardial infarction. Blood Coagul Fibrinolysis 2004; 15:4 97-502. (Abstract)
• Wilhemsen L, Svardsudd K, Korsan-Bengtien K, Larson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. New Engl J Med 1984; 311: 501-5. (Abstract)
• Shea S, Isasi CR, Couch S, et al. Relations of plasma fibrinogen level in children to measures of obesity, the (G-455-->A) mutation in the beta-fibrinogen promoter gene, and family history of ischemic heart disease: the Columbia University BioMarkers Study. Am J Epidemiol 1999; 150: 737-46. (Abstract) / (PDF)
• Pitsavos C, Skoumas J, Dernellis J, et al. Influence of biological factors on lipid and fibrinogen measurements in young men. An epidemiological study in 2009 recruits. Eur Heart J 1998; 19: 1642-7. (Abstract) / (Full Text) / (PDF)
• Mackman N. Role of tissue factor in hemostasis thrombosis and vascular development. Athroscler Thromb Vasc Biol 2004; 24: 1015-22. (Abstract) / (Full Text) / (PDF)
• Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high risk plaque. J Am Coll Cardiol 2005; 46: 937-54. (Abstract) / (PDF)
• Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-7. (Abstract) / (Full Text) / (PDF)
• Morange PE, Blankenberg S, Alessi MC, et al. Atherogene Investigators. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007; 5: 475-82. (PDF)
• Caplice NM, Mueske CS, Kleppe LS, Simari RD. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998; 98: 1051-7. (Abstract) / (Full Text) / (PDF)
• Brodin E, Iversen N, Hansen JB. Impact of native VLDL on tissue factor pathway inhibitor in endothelial cells and interactions between TFPI and lipoprotein lipase. J Lab Clin Med 2006; 147: 167-73. (Abstract) / (Full Text) / (PDF)
• Dahm AE, Andersen TO, Rosendaal F, Sandset PM. A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). J Thromb Haemost 2005; 3: 651-8. (Abstract) / (Full Text) / (PDF)
• Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32: 2575-9. (Abstract) / (Full Text) / (PDF)
• Margaglione M, Cappucci G, Colaizzo D, Vecchione G, Grandone E, Di Minno G. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. Arterioscler Thromb Vasc Biol 2000; 20: 198-203. (Abstract) / (Full Text) / (PDF)
• Samani NJ, Burton P, Mangino M, et al. A genomewide linkage study of 1933 families affected by premature coronary artery disease. The British Heart Foundation (BHF) Family Heart Study. Am J Hum Genet 2005; 77: 1011-20. (Abstract)
• Antal M, Regoly-Merei A, Mesko E, et al. Incidence of risk factors in parents with acute myocardial infarction at young age and in their children. Orv Hetil 2004; 145: 2477-83. (Abstract)
• Kelishadi R, Zadegan NS, Nadery GA, Asgary A, Bashardoust N. Atherosclerosis risk factors in children and adolescents with or without family history of premature coronary artery disease. Med Sci Monit 2002; 8: 425-9. (Abstract)
• Jomini V, Oppliger-Pasquali S, Wietlisbach V, et al. Contribution of major cardiovascular risk factors to familial premature coronary artery disease: the GENECARD Project. J Am Coll Cardiol 2002; 40: 676-84. (Abstract) / (PDF)
• Hauser ER, Crossman DC, Granger CB, et al. Genomewide scan for early-onset coronary artery disease in 438 families. The GENECARD Study. Am J Hum Genet 2004; 75: 436-47. (Abstract) / (Full Text) / (PDF)
• Guran O, Akalın F, Ayabakan C, Dereli FY, Haklar G. High sensitivity C-reactive protein in children at risk for coronary artery disease. Acta Paediatr 2007; 96: 1214-9. (Abstract) / (Full Text) / (PDF)